Risperidone‐Associated Diabetes Mellitus: A Pharmacovigilance Study

Pharmacotherapy - Tập 23 Số 6 - Trang 735-744 - 2003
Elizabeth A. Koller1, James T. Cross1, P. Murali Doraiswamy2, B Schneider1
1Division of Metabolic and Endocrine Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland
2Departments of Psychiatry and Medicine, Duke University Medical Center, Durham, North Carolina.

Tóm tắt

Study Objective. To explore the clinical characteristics of hyperglycemia in patients treated with risperidone.Design. Pharmacovigilance survey of spontaneously reported adverse events in risperidone‐treated patients, with reports of haloperidol‐associated hyperglycemia used as a control.Setting. Government‐affiliated drug evaluation center.Intervention. The Food and Drug Administration MedWatch surveillance program was queried (risperidone, 1993‐February 2002; haloperidol, late 1970s‐February 2002) and results pooled with published cases.Measurements and Main Results. We identified 131 reports of risperidone‐associated hyperglycemia in addition to seven reports of patients with hyperglycemia who received combined risperidone‐haloperidol therapy and six reports of acidosis that occurred in the absence of hyperglycemia. We found 13 reports of haloperidol‐associated hyperglycemia and 11 reports of acidosis without hyperglycemia. Of the reports of risperidone‐associated hyperglycemia (monotherapy), 78 patients had newly diagnosed hyperglycemia, 46 had exacerbated preexisting diabetes, and 7 could not be classified. Mean ± SD age was 39.8 ± 17.4 years (range 8–96 yrs). Patients with new‐onset diabetes (mean ± SD age 34.8 ± 15.7 yrs) were younger than those with preexisting diabetes (mean ± SD age 48.8 ± 17.5 yrs). The overall male:female ratio was 1.5. In most patients, hyperglycemia appeared within 3 months of the start of risperidone therapy. Severity of disease ranged from mild glucose intolerance to diabetic ketoacidosis or hyperosmolar coma. Twenty‐six patients with acidosis or ketosis were reported. Four patients died.Conclusion. Atypical antipsychotic treatment may unmask or precipitate hyperglycemia. Although such cases attributed to clozapine or olanzapine are more numerous than those associated with risperidone, the number for risperidone‐associated hyperglycemia is relatively higher than that observed with the conventional neuroleptic haloperidol.

Từ khóa


Tài liệu tham khảo

2003, Risperidone. Physicians' desk reference, 1786

10.2190/APJP-Y8R6-14GM-K1YT

Krashin D, 1999, Risperidone as adjunct therapy for post‐traumatic stress disorder, Mil Med, 164, 605, 10.1093/milmed/164.8.605

10.4088/JCP.v58n0705

Yatham LN, 2002, The role of novel antipsychotics in bipolar disorders, J Clin Psychol, 63, 10

10.1097/00004850-199503000-00003

Baldessarini RJ, 1996, Goodman and Gilman's: the pharmacological basis of therapeutics, 399

Mannens G, 1993, Absorption, metabolism, and excretion of risperidone in humans, Drug Metab Dispos, 21, 1134

10.1097/00007691-200106000-00008

10.2165/00003088-199733060-00004

10.1007/s00213-002-1056-8

Lindenmayer J‐P, 2001, Hyperglycemia associated with the use of atypical antipsychotics, J Clin Psychiatry, 62, 30

10.1089/cap.1998.8.151

10.1176/appi.psy.41.4.369

10.1016/S0006-3223(01)01087-3

BrescanDW.Risperidone and glucose intolerance [abstr]. Presented at the 150th annual meeting of the American Psychiatric Association San Diego CA. May 1722 1997.

Hidaka S, 1999, Two cases of perforation of the colon in long‐term hospitalized schizophrenic patients during psychotropic drug administration, Clin Psychiatry, 41, 425

10.1016/0735-6757(89)90252-0

10.1016/0735-6757(91)90216-7

10.1016/0735-6757(95)90171-X

Miyahira Y, 1998, A case report of death from neuroleptic malignancy syndrome due to long‐acting haloperidol, Kyushu Neuropsychiatry, 44, 322

10.1016/S1164-6756(00)87583-0

10.1016/S1525-8610(04)70192-9

Dohin‐Caplanne S, 1995, Severe hepatitis complicating exercise‐induced heatstroke favored by treatment with neuroleptic and anticholinergic drugs (French), Gastroenterol Clin Biol, 19, 637

10.1016/0735-6757(88)90252-5

10.1016/S0735-6757(99)90254-1

Kenny SJ, 1995, Diabetes in America, 2nd ed. Publication no. 95–1468, 47

Ammon HR, 1973, Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat, J Pharmacol Exp Ther, 187, 423

10.1016/S0002-9343(01)00806-3

10.2165/00002018-200124130-00004

10.1111/j.1600-0404.1984.tb00804.x

Turnbull DM, 1985, The effect of valproate on blood metabolite concentrations in spontaneously diabetic, ketoacidotic, BB/E Wistar rats, Diabetes Res, 2, 45

10.1001/jama.281.9.824

10.1001/jama.287.17.2215

10.1056/NEJM200006153422410

10.1097/00004583-200205000-00004

10.1016/S0002-9343(01)01000-2

10.1592/phco.22.11.841.33629

Procyshyn RM, 2000, New‐onset diabetes associated with quetiapine, Can J Psychiatry, 45, 668

Sobel M, 1999, New‐onset diabetes associated with the initiation of quetiapine treatment, J Clin Psychol, 60, 556

10.1038/sj.mp.4000566

10.4088/JCP.v60n1112

10.4088/JCP.v61n1006

10.1016/S0924-977X(01)00108-0

10.1016/S0006-8993(01)03026-8

10.1016/S0304-3940(99)00712-0

Koller EA CrossJT DoraiswamyPM MalozowskiSN.Pancreatitis associated with atypical antipsychotics: from the FDA MedWatch surveillance system.Pharmacotherapy in press.

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 23 Số 6

735-744

Thông tin tác giả